Literature DB >> 21795477

The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.

Atsushi Uesugi1, Ken-Ichi Kozaki, Tomohiko Tsuruta, Mayuko Furuta, Kei-Ichi Morita, Issei Imoto, Ken Omura, Johji Inazawa.   

Abstract

The incidence of oral squamous cell carcinoma (OSCC) is rising rapidly in developed countries, posing a growing challenge due to the poor management of this type of malignancy at present. In this study, we profiled tumor suppressive microRNAs (miRNAs) that are silenced by DNA hypermethylation in OSCC using a function-based screening approach. This approach employed a cell proliferation assay for 327 synthetic miRNAs in two OSCC cell lines. Among the 110 miRNAs identified in this set that exhibited inhibitory properties, we compared DNA methylation and expression status in a wider panel of OSCC cell lines and primary tumor tissues, resulting in the identification of miR-218 and miR-585 as functionally significant miRNA genes that are frequently silenced in OSCC by DNA hypermethylation. Ectopic expression of miR-218 and miR-585 in OSCC cells lacking endogenous expression reduced cell growth in part through caspase-mediated apoptosis. Notably, miR-218 reduced levels of the rapamycin-insensitive component of mTOR, Rictor, in a manner associated with a suppression of Akt S473 phosphorylation. Together our findings define miR-585 as a tumor suppressive function that is often epigenetically silenced in OSCC, and they identify Rictor as a novel target of miR-218, suggesting that activation of the mTOR-Akt signaling pathway induced by Rictor contributes centrally to oral carcinogenesis. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795477     DOI: 10.1158/0008-5472.CAN-11-0368

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  108 in total

Review 1.  Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Authors:  Gaetano Santulli; Hana Totary-Jain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer.

Authors:  Mayuko Kato; Akira Kurozumi; Yusuke Goto; Ryosuke Matsushita; Atsushi Okato; Rika Nishikawa; Ichiro Fukumoto; Keiichi Koshizuka; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

3.  microRNA-218 expression and its association with the clinicopathological characteristics of patients with cervical cancer.

Authors:  Bei-Bei Tang; Shui-Yi Liu; Y U Zhan; Li-Qing Wei; Xiao-Lu Mao; Jin Wang; L I Li; Zhong-Xin Lu
Journal:  Exp Ther Med       Date:  2015-04-28       Impact factor: 2.447

4.  Learning regulatory programs by threshold SVD regression.

Authors:  Xin Ma; Luo Xiao; Wing Hung Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-20       Impact factor: 11.205

5.  Downregulation of miR-185 and upregulation of miR-218 expression may be potential diagnostic and prognostic biomarkers of human chondrosarcoma.

Authors:  Peyman Karimi Goudarzi; Afshin Taheriazam; Saeid Asghari; Mohammad Jamshidi; Mohammadreza Shakeri; Emad Yahaghi; Alireza Mirghasemi
Journal:  Tumour Biol       Date:  2015-09-18

6.  MicroRNA-218 inhibits the proliferation, migration, and invasion and promotes apoptosis of gastric cancer cells by targeting LASP1.

Authors:  Le-Le Wang; Lei Wang; Xiao-Ying Wang; Di Shang; Sheng-Jie Yin; Li-Li Sun; Hong-Bo Ji
Journal:  Tumour Biol       Date:  2016-09-30

7.  MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene.

Authors:  Xinqi He; Yujuan Dong; Chung Wah Wu; Zengren Zhao; Simon S M Ng; Francis K L Chan; Joseph J Y Sung; Jun Yu
Journal:  Mol Med       Date:  2013-02-08       Impact factor: 6.354

Review 8.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

Review 9.  DNA methylation and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Mol Oncol       Date:  2012-08-10       Impact factor: 6.603

10.  MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.

Authors:  Jing Xie; Fei Yu; Dan Li; Xuchao Zhu; Xiaoping Zhang; Zhongwei Lv
Journal:  Tumour Biol       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.